Literature DB >> 7825032

Immunogenicity of hepatitis B vaccine in premature infants.

S Sanpavat1, Y Poovorawan, S Chittinand, S Bhongsvej, P Thaithumyanon.   

Abstract

The immunogenicity of plasma-derived hepatitis B vaccine was studied in 39 premature neonates, whose weights were 1,800-2,400 g and gestational ages 32-37 weeks. All maternal antiHBc antibody were negative. Dosage of 5 micrograms of hepatitis B vaccine (Pasteur vaccine) was given at 0, 1, 2 and 12 months after birth. At the ages of 1, 2, 4, 9, 12 and 13 months, antiHBs antibody was found in 7.7%, 20%, 69.7%, 81.4%, 77.3% and 89.5%, respectively, while the geometric mean titer in this seropositive group, starting at age 2 months was 37, 121, 113, 69 and 1,016 mIU/ml. There was no severe reaction attributed to the vaccination. The result indicated that the vaccine was immunogenic. Although the conversion rate was low after primary injection, a satisfactory response developed at age 4 months after 3 doses of vaccine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7825032

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  2 in total

1.  Immunogenicity of hepatitis B vaccine in preterm infants.

Authors:  O Blondheim; D Bader; M Abend; M Peniakov; D Reich; I Potesman; R Handsher; I Gidoni; N Linder
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-11       Impact factor: 5.747

2.  Hepatitis B response of premature infants after primary and booster immunisation with a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus/haemophilus influenzae type B vaccine.

Authors:  Felix Omeñaca; Jose Garcia-Sicilia; Reyes Boceta; Pilar García-Corbeira
Journal:  Infect Dis Obstet Gynecol       Date:  2010-04-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.